重度抑郁症患者肠道菌群代谢产物水平及其与炎症因子的相关性

王丽英; 陈晶

doi:10.16766/j.cnki.issn.1674-4152.003683

重度抑郁症患者肠道菌群代谢产物水平及其与炎症因子的相关性

doi: 10.16766/j.cnki.issn.1674-4152.003683

王丽英,
陈晶^,

绍兴市第七人民医院精神科，浙江绍兴 312000

基金项目:

浙江省医药卫生科技计划项目 2023KY1272

详细信息

通讯作者:
陈晶，E-mail：406886906@qq.com

中图分类号: R749.4
计量
- 文章访问数: 20
- HTML全文浏览量: 15
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2024-01-03

Metabolite level of intestinal flora in patients with major depression and its correlation with inflammatory factors

WANG Liying,
CHEN Jing^,

Department of Psychiatry, Shaoxing Seventh People ' s Hospital, Shaoxing, Zhejiang 312000, China

摘要

摘要: 目的分析重度抑郁症(MDD)患者的肠道菌群特征及其代谢产物水平，并探讨其与炎症因子的关系。方法选取2020年5月—2023年5月于绍兴市第七人民医院接受治疗的98例MDD患者作为研究对象，再选取同期于该院接受健康检查的50例健康人群作为对照组。对比MDD患者与健康人群的肠道菌群代谢产物水平以及炎症因子水平差异，采用Pearson相关性分析肠道菌群代谢产物水平及其与炎症因子的关系。结果 MDD组的IL-1β[(55.48±12.08)ng/L]等炎症因子水平高于对照组[(42.15±10.03)ng/L, t=7.124，P < 0.001]，MDD组的氧化三甲胺(TMAO)水平[(3.25±0.71)μmol/L]高于对照组[(1.37±0.24)μmol/L, t=23.694，P < 0.001]，MDD组短链脂肪酸(SCFAs)总量[(18.26±2.94)μg/g]均低于对照组[(22.03±3.25)μg/g，t=6.889，P < 0.001]；MDD组的TMAO和IL-1β(r=0.404)、IL-6(r=0.503)、CRP(r=0.454)水平呈正相关，和TNF-α水平(r=-0.348)呈负相关，SCFAs和IL-1β(r=-0.478)、IL-6(r=-0.378)、CRP水平(r=-0.416)均呈负相关关系(P < 0.05)。结论 MDD患者肠道菌群代谢产物TMAO、SCFAs的水平与炎症因子水平密切相关，恢复肠道菌群代谢产物的平衡可在MDD的治疗中发挥重要作用。
- 重度抑郁症 /
- 肠道菌群 /
- 菌群代谢产物 /
- 炎症因子 /
- 短链脂肪酸 /
- 氧化三甲胺
Abstract: Objective To analyze the characteristics of intestinal flora and the level of its metabolites in patients with major depressive disorder (MDD), and to explore its relationship with inflammatory factors. Methods A total of 98 MDD patients who were treated in Shaoxing Seventh People ' s Hospital from May 2020 to May 2023 were selected as the research object and 50 healthy people who received health examination in the same period were selected as the control group. The levels of intestinal flora metabolites and inflammatory factors between MDD patients and healthy people were compared, and the relationship between intestinal flora metabolites and inflammatory factors was analyzed by Pearson correlation. Results The levels of IL-1β[(55.48±12.08) ng/L] and other inflammatory factors in the MDD group were higher than those in the control group [(42.15±10.03) ng/L, t=7.124, P < 0.001]. The trimetlylamine oxide (TMAO) level in the MDD group [(3.25±0.71) μmol/L] was higher than that in the control group [(1.37±0.24) μmol/L, t=23.694, P < 0.001]. The total amount of short chain fatty acids (SCFAs) in the MDD group [(18.26±2.94) μg/g] was lower than that in the control group [(22.03±3.25) μg/g, t=6.889, P < 0.001]. In the MDD group, the TMAO level was positively correlated with the level of IL-1β (r=0.404), IL-6 (r=0.503), and CRP (r=0.454), and negatively correlated with TNF-αlevel (r=-0.348). The levels of SCFAs and IL-1β (r=-0.478), IL-6 (r=-0.378), and CRP (r=-0.416) were negatively correlated (P < 0.05). Conclusion The levels of TMAO and SCFAs in the intestinal flora of MDD patients are closely related to the levels of inflammatory factors, and restoring the balance of intestinal flora metabolites plays an important role in the treatment of MDD.
- Major depressive disorder /
- Intestinal flora /
- Metabolites of flora /
- Inflammatory factor /
- Short chain fatty acids /
- Trimetlylamine oxide
利益冲突 无

HTML全文

表 1 对照组和MDD组的一般资料比较

Table 1. Comparison of general data between the control group and the MDD group

项目	对照组(n=50)	MDD组(n=98)	统计量	P值
年龄(x±s，岁)	44.55±7.26	45.31±8.06	0.580^a	0.563
性别[例(%)]			0.483^b	0.487
男性	23(46.00)	51(52.04)
女性	27(54.00)	47(47.96)
教育程度(x±s，年)	12.76±3.72	13.42±3.11	1.077^a	0.285
BMI(x±s)	21.89±2.51	22.27±3.02	0.812^a	0.419
吸烟史[例(%)]	2(4.00)	3(3.06)	0.033^b	0.856
饮酒史[例(%)]	3(6.00)	8(8.16)	0.021^b	0.886
家族史[例(%)]	0	11(11.22)	4.451^b	0.033
婚姻状况[例(%)]			1.266^b	0.509
已婚	36(72.00)	62(63.27)
未婚	12(24.00)	32(32.65)
其他	2(4.00)	4(4.08)
注：^a为t值，^b为χ²值。

下载: 导出CSV

表 2 对照组和MDD组的肠道菌群分布比较(x±s，%)

Table 2. Comparison of intestinal flora distribution between the control group and the MDD group(x±s, %)

组别	例数	门分类				属分类
组别	例数	厚壁菌门	放线菌门	变形菌门	拟杆菌门	双歧杆菌属	乳酸杆菌属	普雷沃氏菌属	瘤胃菌属	粪球菌属
对照组	50	55.23±2.23	24.88±1.15	10.07±0.86	2.74±0.41	17.02±1.18	11.73±0.54	7.15±1.40	6.57±0.71	9.12±0.53
MDD组	98	47.25±1.76	30.15±2.07	14.22±0.99	6.25±1.18	13.52±1.06	8.14±0.71	12.52±3.22	5.13±0.66	7.86±0.83
t值		22.042	19.894	26.356	26.480	17.652	34.267	14.102	11.947	11.204
P值		< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

下载: 导出CSV

表 3 对照组和MDD组的炎症因子水平比较(x±s)

Table 3. Comparison of levels of inflammatory factors between the control group and the MDD group(x±s)

组别	例数	IL-1β(ng/L)	IL-6(ng/L)	TNF-α(ng/L)	CRP(mg/L)
对照组	50	42.15±10.03	26.13±8.11	50.34±7.08	4.12±0.87
MDD组	98	55.48±12.08	29.87±3.62	45.19±8.89	7.15±1.33
t值		7.124	3.107	3.829	16.632
P值		< 0.001	0.003	< 0.001	< 0.001

下载: 导出CSV

表 4 对照组和MDD组的肠道菌群代谢产物水平比较(x±s)

Table 4. Comparison of intestinal flora metabolites between the control group and the MDD group(x±s)

组别	例数	TMAO(μmol/L)	SCFAs(μg/g)
组别	例数	TMAO(μmol/L)	丁酸	丙酸	乙酸	总量
对照组	50	1.37±0.24	4.25±0.61	4.48±0.64	13.25±1.57	22.03±3.25
MDD组	98	3.25±0.71	2.41±0.34	3.65±0.42	12.45±1.84	18.26±2.94
t值		23.694	19.816	8.303	2.763	6.889
P值		< 0.001	< 0.001	< 0.001	0.007	< 0.001

下载: 导出CSV

表 5 MDD组肠道菌群代谢产物水平与炎症因子水平的相关性

Table 5. Correlation analysis between the intestinal flora metabolites and inflammatory factor levels in the MDD group

项目	TMAO		SCFAs		双歧杆菌		乳酸杆菌
项目	r值	P值	r值	P值	r值	P值	r值	P值
IL-1β	0.404	< 0.001	-0.478	< 0.001	-0.555	< 0.001	-0.459	< 0.001
IL-6	0.503	< 0.001	-0.378	< 0.001	-0.489	< 0.001	-0.450	< 0.001
TNF-α	-0.348	< 0.001	0.290	0.004	0.474	< 0.001	0.541	< 0.001
CRP	0.454	< 0.001	-0.416	< 0.001	-0.417	< 0.001	-0.382	< 0.001

下载: 导出CSV

参考文献(28)

[1]	韩振翔, 祁丽丽, 侯臻臻, 等. 醒神解郁方对卒中后中重度抑郁患者血清Th17/Treg免疫失衡及生活能力干预研究[J]. 中华全科医学, 2021, 19(2): 217-220. doi: 10.16766/j.cnki.issn.1674-4152.001771 HAN Z X, QI L L, HOU Z Z, et al. Clinical effect of Xinshen Jieyu Decoction in the imbalance of Th17/Treg and Barthel index in the moderate or severe post-stroke depression patients[J]. Chinese Journal of General Practice, 2021, 19(2): 217-220. doi: 10.16766/j.cnki.issn.1674-4152.001771
[2]	KANG S G, CHO S E. Neuroimaging biomarkers for predicting treatment response and recurrence of major depressive disorder[J]. Int J Mol Sci, 2020, 21(6): 2148. doi: 10.3390/ijms21062148
[3]	唐恒, 马开利, 晏远智. 不同剂量沃替西汀治疗重度抑郁症的系统评价[J]. 中国医院药学杂志, 2020, 40(3): 315-321. TANG H, MA K L, YAN Y Z. Systematicevaluation of different doses of vortioxetine in the treatment of major depressive disorder[J]. Chinese Journal of Hospital Pharmacy, 2020, 40(3): 315-321.
[4]	TROUBAT R, BARONE P, LEMAN S, et al. Neuroinflammation and depression: a review[J]. Eur J Neurosci, 2021, 53(1): 151-171. doi: 10.1111/ejn.14720
[5]	TING E Y, YANG A C, TSAI S J. Role of interleukin-6 in depressive disorder[J]. Int J Mol Sci, 2020, 21(6): 2194. DOI: 10.3390/ijms21062194.
[6]	VALLES-COLOMER M, FALONY G, DARZI Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression[J]. Nat Microbiol, 2019, 4(4): 623-632. doi: 10.1038/s41564-018-0337-x
[7]	LO B C, CHEN G Y, NÙÑEZ G, et al. Gut microbiota and systemic immunity in health and disease[J]. Int Immunol, 2021, 33(4): 197-209. doi: 10.1093/intimm/dxaa079
[8]	ZHUANG Z, YANG R, WANG W, et al. Associations between gut microbiota and Alzheimer ' s disease, major depressive disorder, and schizophrenia[J]. J Neuroinflammation, 2020, 17(1): 288. doi: 10.1186/s12974-020-01961-8
[9]	KARAKULA-JUCHNOWICZ H, ROG J, JUCHNOWICZ D, et al. The study evaluating the effect of probiotic supplementation on the mental status, inflammation, and intestinal barrier in major depressive disorder patients using gluten-free or gluten-containing diet (SANGUT study): a 12-week, randomized, double-blind, and placebo-controlled clinical study protocol[J]. Nutr J, 2019, 18(1): 50. doi: 10.1186/s12937-019-0475-x
[10]	CAI J, SUN L, GONZALEZ F J. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis[J]. Cell Host Microbe, 2022, 30(3): 289-300. doi: 10.1016/j.chom.2022.02.004
[11]	TILG H, ADOLPH T E, TRAUNER M. Gut-liver axis: pathophysiological concepts and clinical implications[J]. Cell Metab, 2022, 34(11): 1700-1718. doi: 10.1016/j.cmet.2022.09.017
[12]	UHER R, PAYNE J L, PAVLOVA B, et al. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV[J]. Depress Anxiety, 2014, 31(6): 459-471. doi: 10.1002/da.22217
[13]	中国中西医结合学会神经科专业委员会. 抑郁症中西医结合诊疗专家共识[J]. 中国中西医结合杂志, 2020, 40(2): 141-148.
[14]	HAMILTON M. A rating scale for depression[J]. J Neurol Neurosurg Psychiatry, 1960, 23(1): 56-62. doi: 10.1136/jnnp.23.1.56
[15]	DOWLING L R, STRAZZARI M R, KEELY S, et al. Enteric nervous system and intestinal epithelial regulation of the gut-brain axis[J]. J Allergy Clin Immunol, 2022, 150(3): 513-522. doi: 10.1016/j.jaci.2022.07.015
[16]	SOCAŁA K, DOBOSZEWSKA U, SZOPA A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders[J]. Pharmacol Res, 2021, 172: 105840. DOI: 10.1016/j.phrs.2021.105840.
[17]	CASPANI G, SWANN J. Small talk: microbial metabolites involved in the signaling from microbiota to brain[J]. Curr Opin Pharmacol, 2019, 48: 99-106. doi: 10.1016/j.coph.2019.08.001
[18]	SILVA Y P, BERNARDI A, FROZZA R L. The role of short-chain fatty acids from gut microbiota in gut-brain communication[J]. Front Endocrinol (Lausanne), 2020, 11: 25. doi: 10.3389/fendo.2020.00025
[19]	JU S, SHIN Y, HAN S, et al. The gut-brain axis in schizophrenia: the implications of the gut microbiome and SCFA production[J]. Nutrients, 2023, 15(20): 4391. doi: 10.3390/nu15204391
[20]	KNUDSEN J K, BUNDGAARD-NIELSEN C, HJERRILD S, et al. Gut microbiota variations in patients diagnosed with major depressive disorder: a systematic review[J]. Brain Behav, 2021, 11(7): e02177. DOI: 10.1002/brb3.2177.
[21]	RONG H, XIE X H, ZHAO J, et al. Similarly in depression, nuances of gut microbiota: evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients[J]. J Psychiatr Res, 2019, 113: 90-99. doi: 10.1016/j.jpsychires.2019.03.017
[22]	LAI W T, ZHAO J, XU S X, et al. Shotgun metagenomics reveals both taxonomic and tryptophan pathway differences of gut microbiota in bipolar disorder with current major depressive episode patients[J]. J Affect Disord, 2021, 278: 311-319. doi: 10.1016/j.jad.2020.09.010
[23]	吴振宁, 王琦, 秦雪梅, 等. 肠道菌群及其代谢产物在中药治疗抑郁症中的研究进展[J]. 中草药, 2023, 54(14): 4713-4721. WU Z N, WANG Q, QIN X M, et al. Research progress on gut microbiota and its metabolites in treating depression with traditional Chinese medicine[J]. Chinese Traditional and Herbal Drugs, 2023, 54(14): 4713-4721.
[24]	PEIRCE J M, ALVIÑA K. The role of inflammation and the gut microbiome in depression and anxiety[J]. J Neurosci Res, 2019, 97(10): 1223-1241. doi: 10.1002/jnr.24476
[25]	BEUREL E, TOUPS M, NEMEROFF C B. The bidirectional relationship of depression and inflammation: double trouble[J]. Neuron, 2020, 107(2): 234-256. doi: 10.1016/j.neuron.2020.06.002
[26]	WEI H, YU C, ZHANG C, et al. Butyrate ameliorates chronic alcoholic central nervous damage by suppressing microglia-mediated neuroinflammation and modulating the microbiome-gut-brain axis[J]. Biomed Pharmacother, 2023, 160: 114308. DOI: 10.1016/j.biopha.2023.114308.
[27]	MEINITZER S, BARANYI A, HOLASEK S, et al. Sex-specific associations of trimethylamine-N-oxide and zonulin with signs of depression in carbohydrate malabsorbers and nonmalabsorbers[J]. Dis Markers, 2020, 2020: 7897240. DOI: 10.1155/2020/7897240.
[28]	MUDIMELA S, VISHWANATH N K, PILLAI A, et al. Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders[J]. Drug Discov Today, 2022, 27(11): 103334. DOI: 10.1016/j.drudis.2022.08.002.